Chimera

TScan Therapeutics Presents Promising Updated Phase 1 Clinical Results on TSC-100 and TSC-101 at the 2024 Tandem Meetings of ASTCT and CIBMTR

Retrieved on: 
Monday, February 26, 2024

“We are excited to report updated data from our heme program, with eight patients across our treatment arms and six patients in our control arm.

Key Points: 
  • “We are excited to report updated data from our heme program, with eight patients across our treatment arms and six patients in our control arm.
  • We remain encouraged to see that no relapses have occurred to date in treated patients, four of whom have been on the study for over ten months.
  • Unfortunately, roughly 40% of patients relapse following HCT, at which point there are limited treatment options and a poor prognosis.
  • A replay will be made available on the “ Events and Presentations ” section of the Company’s investor relations website at ir.tscan.com .

Research Finds IT Leaders Are Still Facing Challenges When It Comes to Data Understanding and Analysis

Retrieved on: 
Thursday, February 29, 2024

Almost a quarter (23%), however, feel data is still only being utilized somewhat effectively and they could be doing more with it.

Key Points: 
  • Almost a quarter (23%), however, feel data is still only being utilized somewhat effectively and they could be doing more with it.
  • Used to gain insights into customer behavior, market trends, and internal operations, today’s businesses are reliant on data to make timely, strategic decisions.
  • A further 29% are also still grappling with the time that is associated with managing and analyzing data.
  • The research surveyed 1,200 business and IT leaders in the United Kingdom, United States, France, and Germany from companies with annual revenue exceeding $500 million.

CareDx Showcases Digital Solutions and Pipeline in Cellular Transplant and Therapy Monitoring at the 2024 Tandem Meetings

Retrieved on: 
Wednesday, February 21, 2024

“Cellular transplant centers are recognizing the value of our digital and patient monitoring solutions, and we look forward to sharing our latest advancements as we work to expand our presence in this dynamic ecosystem,” said Kashif Rathore, Chief of Patient and Digital Solutions at CareDx.

Key Points: 
  • “Cellular transplant centers are recognizing the value of our digital and patient monitoring solutions, and we look forward to sharing our latest advancements as we work to expand our presence in this dynamic ecosystem,” said Kashif Rathore, Chief of Patient and Digital Solutions at CareDx.
  • CareDx will be showcasing its broad portfolio of digital health solutions that address needs in the cellular transplant and therapy ecosystem including workflow management, regulatory reporting, medication management, and remote patient monitoring.
  • Product solution areas include:
    Ottr® Cellular: Designed as a workflow management solution for hematopoietic cellular transplant and cellular therapy centers.
  • Poster 299: Analytical Validation of AlloCell cfDNA - a Highly Sensitive, Precise, and Accurate Cell-Free DNA-Based Test for Allogeneic Cell Therapy Monitoring.

Carrick Therapeutics Announces First Patient Dosed in Phase 1b/2 Clinical Trial of Samuraciclib in Combination with Vepdegestrant in Patients with Advanced Breast Cancer

Retrieved on: 
Wednesday, February 14, 2024

“We’re excited to expand clinical development of samuraciclib with our Phase 1b/2 clinical trial evaluating the combination of samuraciclib and vepdegestrant, another step forward in addressing an important need for patients with advanced breast cancer,” said Tim Pearson, Chief Executive Officer of Carrick Therapeutics.

Key Points: 
  • “We’re excited to expand clinical development of samuraciclib with our Phase 1b/2 clinical trial evaluating the combination of samuraciclib and vepdegestrant, another step forward in addressing an important need for patients with advanced breast cancer,” said Tim Pearson, Chief Executive Officer of Carrick Therapeutics.
  • “We believe there is great potential for this combination treatment, based on the encouraging initial clinical trial data for vepdegestrant and Pfizer’s deep expertise in developing treatments for breast cancer.”
    The Phase 1b/2 clinical trial has two parts.
  • In Phase 1b, escalating doses of samuraciclib and vepdegestrant will be tested to determine appropriate doses of each therapy to be used in combination.
  • This clinical trial evaluating the novel combination of samuraciclib and vepdegestrant is being conducted as part of the TACTIVE-U study in collaboration with Arvinas and Pfizer under a clinical trial collaboration and supply agreement.

Arvinas and Pfizer’s Vepdegestrant (ARV-471) Receives FDA Fast Track Designation for the Treatment of Patients with ER+/HER2- Metastatic Breast Cancer

Retrieved on: 
Tuesday, February 6, 2024

NEW HAVEN, Conn. and NEW YORK, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the investigation of vepdegestrant (ARV-471) for monotherapy in the treatment of adults with estrogen receptor (ER) positive/human growth epidermal growth factor 2 (HER2) negative (ER+/HER2-) locally advanced or metastatic breast cancer previously treated with endocrine-based therapy. Vepdegestrant is a novel oral PROteolysis Targeting Chimera (PROTAC®) ER degrader that is being jointly developed by Arvinas and Pfizer.

Key Points: 
  • Vepdegestrant is a novel oral PROteolysis Targeting Chimera (PROTAC®) ER degrader that is being jointly developed by Arvinas and Pfizer.
  • As described by the FDA, Fast Track is a process designed to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need.
  • “The receipt of Fast Track designation reinforces the potential of vepdegestrant to provide an important new therapeutic option for people with ER+/HER2- breast cancer whose disease has progressed,” said Roger Dansey, M.D., Chief Development Officer, Oncology, Pfizer.
  • “We are proud to continue our legacy of developing innovative treatment options for people impacted by metastatic breast cancer and look forward to working with the FDA as we advance our development program for vepdegestrant.”

Jasper Therapeutics Presents Positive Final Results from Phase 1 Study of Briquilimab in Patients with AML or MDS Undergoing Hematopoietic Cell Transplant in Oral Presentation at ASH 2023

Retrieved on: 
Sunday, December 10, 2023

The study enrolled 32 adult patients (62 to 79 years) with AML in CR (n=13), MDS (n=16), or AML not in CR (n=3).

Key Points: 
  • The study enrolled 32 adult patients (62 to 79 years) with AML in CR (n=13), MDS (n=16), or AML not in CR (n=3).
  • Peripheral blood grafts were infused on TD0 (10-14 days after briquilimab).
  • Further, briquilimab dosing resulted in predictable pharmacokinetics and allowed donor cell infusion 9-14 days after administration, and all patients who engrafted achieved neutrophil recovery before TD +26.
  • The 2a portion of the study is ongoing and continues to enroll patients.

Arvinas and Pfizer Announce Interim Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®) and Plans to Expand Vepdegestrant Development Program

Retrieved on: 
Tuesday, December 5, 2023

NEW HAVEN, Conn. and NEW YORK, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced clinical data for vepdegestrant (ARV-471), a novel oral PROteolysis TArgeting Chimera (PROTAC®) estrogen receptor (ER) degrader, in combination with palbociclib (IBRANCE®). Interim results from the Phase 1b combination cohort demonstrate encouraging clinical activity in heavily pre-treated patients with a median of four lines of therapy across disease settings with locally advanced or metastatic ER positive/human epidermal growth factor 2 (HER2) negative (ER+/HER2-) breast cancer. These data will be presented in a spotlight presentation at the 2023 San Antonio Breast Cancer Symposium (SABCS).

Key Points: 
  • These data will be presented in a spotlight presentation at the 2023 San Antonio Breast Cancer Symposium (SABCS).
  • The results from this trial evaluating vepdegestrant in combination with palbociclib help advance our goals of benefitting patients with ER+/HER2- breast cancer.
  • “Collectively, the data presented this year at SABCS for vepdegestrant, especially in combination with palbociclib, show the potential of this investigational innovative therapeutic option.
  • A conference call and webcast will be held with executives from Arvinas and Pfizer to discuss the data presented at SABCS.

Arvinas and Pfizer Announce Updated Vepdegestrant (ARV-471) Data to be Presented at the 2023 San Antonio Breast Cancer Symposium

Retrieved on: 
Tuesday, November 28, 2023

NEW HAVEN, Conn. and NEW YORK, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced that updated clinical trial data for vepdegestrant (ARV-471) will be presented at the 2023 San Antonio Breast Cancer Symposium (SABCS). Vepdegestrant is a novel oral PROteolysis TArgeting Chimera (PROTAC®) estrogen receptor (ER) degrader currently being investigated for the potential treatment of patients with locally advanced or metastatic estrogen receptor (ER) positive/human epidermal growth factor receptor 2 (HER2) negative (ER+/HER2-) breast cancer. Arvinas and Pfizer are collaborating to develop and commercialize vepdegestrant.

Key Points: 
  • -- Six abstracts have been accepted for presentation, including updated data on vepdegestrant alone and in combination with palbociclib (IBRANCE®) --
    NEW HAVEN, Conn. and NEW YORK, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced that updated clinical trial data for vepdegestrant (ARV-471) will be presented at the 2023 San Antonio Breast Cancer Symposium (SABCS).
  • Arvinas and Pfizer are collaborating to develop and commercialize vepdegestrant.
  • Data from the Phase 1b study assessing vepdegestrant in combination with palbociclib (IBRANCE®) will be presented in a spotlight session on December 7, 2023.
  • An update on the Phase 2 vepdegestrant monotherapy (VERITAC) study will be presented in a poster presentation alongside four other posters during the symposium held from December 5-9, 2023, in San Antonio, Texas.

Tune Therapeutics Presents First Data Supporting TUNE-401: a First-in-Class Epigenetic Silencer for Hepatitis B

Retrieved on: 
Wednesday, December 6, 2023

Leading epigenome editing company Tune Therapeutics presented data in support of its chronic Hepatitis B Virus (HBV) program, demonstrating the ability to durably silence essential mechanisms of viral replication and persistence across a range of model systems.

Key Points: 
  • Leading epigenome editing company Tune Therapeutics presented data in support of its chronic Hepatitis B Virus (HBV) program, demonstrating the ability to durably silence essential mechanisms of viral replication and persistence across a range of model systems.
  • Importantly, the TEMPO platform does this via epigenetic processes, and without cutting, damaging, or altering genomic DNA sequences in any way.
  • “Through the richness of these data sets, we found multiple repression candidates that worked well in both contexts.
  • As such, they represent the gold standard for assessing the dose and efficacy for liver-directed therapeutics ahead of human clinical trials.

New Indie World Showcase Uncorks the Bottle on More Than a Dozen Upcoming Nintendo Switch Games

Retrieved on: 
Tuesday, November 14, 2023

In the latest Indie World showcase , Nintendo presented an exciting lineup of indie games that will be arriving to the Nintendo Switch family of systems in 2023 and beyond.

Key Points: 
  • In the latest Indie World showcase , Nintendo presented an exciting lineup of indie games that will be arriving to the Nintendo Switch family of systems in 2023 and beyond.
  • View the full release here: https://www.businesswire.com/news/home/20231114920688/en/
    Shantae Advance: Risky Revolution launches for Nintendo Switch in 2024.
  • For the latest news and updates about indie games on Nintendo Switch, follow the Indie World X account @IndieWorldNA and check out https://www.nintendo.com/us/indie-world/news/ .
  • * Any Nintendo Switch Online membership (sold separately) and Nintendo Account required for online features.